Bafetinib-INNO-406-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBafetinibCat. No.: HY-50868CAS No.: 859212-16-1Synonyms: INNO-406; NS-187分式: CHFNO分量: 576.62作靶点: Bcr-Abl; Autophagy作通路: Protein Tyrosine Kinase/RTK; Autophagy储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month

2、溶解性数据体外实验 DMSO : 42 mg/mL (72.84 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.7342 mL 8.6712 mL 17.3424 mL5 mM 0.3468 mL 1.7342 mL 3.4685 mL10 mM 0.1734 mL 0.8671 mL 1.7342 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Bafetin

3、ib具有抗肿瘤活性的 Lyn/Bcr-Abl 酪氨酸激酶抑制剂。1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE Science. 2017 Dec 1;358(6367). Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. J Cancer. 2019; 10(5): 11971208. Technical University of Munich. 24.01.2018.See more customer validations on HYPERLINK / www.MedChemERE

4、FERENCES1. Grace MS, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br JPharmacol. 2014 Aug;171(16):3881-3894.2. Kimura S, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent

5、for imatinib-resistantleukemia. Blood. 2005 Dec 1;106(12):3948-3954.3. Kamitsuji Y, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008, 15(11), 1712-2172.4. Yokota A, et al. INNO-406, a nov

6、el BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in thecentral nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007, 109(1), 306-314.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820